Newcorp

Newron Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The company's flagship product, Xadago (safinamide), is approved globally for the treatment of Parkinson's disease as an add-on therapy to levodopa. Newron is also advancing a clinical pipeline targeting high unmet needs, including evenamide for the treatment of schizophrenia and potentially Rett syndrome. Headquartered in Italy, the company leverages its expertise in ion channel modulation and neurotransmitter regulation to address complex neurological disorders.